Micro-invasive canaloplasty: OftalMedica is the new iTrack distributor
01/07/2019
01/07/2019
We are proud to announce that starting July 1st 2019 OftalMedica is the sole and exclusive importer and distributor in Italy of the entire Ellex line which includes ophthalmic lasers, ultrasound scanners and iTrack micro-invasive canaloplasty catheter.
Corneal dystrophies, a contraindication for refractive surgery on a global scale
28/05/2019
28/05/2019
Corneal dystrophies represent a strong contraindication to refractive surgery, unfortunately in some cases they are difficult if not impossible to diagnose: today there is an effective genetic test in 100% of cases.
Maculopathy, the 2RT laser is effective in 3 out of 4 patients
21/05/2019
21/05/2019
Age-related macular degeneration is the leading cause of blindness in industrialized countries, the LEAD study conducted by the Center for Eye Research Australia (CERA) and published in Ophtalmology reveals effective therapy for the first time.
Reflex, the laser certified for the treatment of floaters
16/05/2019
16/05/2019
Floaters are a very common disorder caused by the natural process of vitreous degeneration, which is why it can be easy to underestimate their debilitating impact in symptomatic patients.
Floaters influence the quality of life of the patient according to their size, density and position, characteristics that also determine whether they can be treated successfully.
The Reflex laser is a safe and effective treatment for floaters with coaxial lighting and a higher efficiency energy profile designed and certified for this type of therapy.
Once focused on the floater, the laser creates a plasma bubble that vaporizes the collagen and hyaluronic acid molecules in the floater, turning them into gas that will naturally be reabsorbed by the eye.
Since laser energy is targeted to inert proteins and not to living tissue, inflammation is not induced.
Floaters influence the quality of life of the patient according to their size, density and position, characteristics that also determine whether they can be treated successfully.
The Reflex laser is a safe and effective treatment for floaters with coaxial lighting and a higher efficiency energy profile designed and certified for this type of therapy.
Once focused on the floater, the laser creates a plasma bubble that vaporizes the collagen and hyaluronic acid molecules in the floater, turning them into gas that will naturally be reabsorbed by the eye.
Since laser energy is targeted to inert proteins and not to living tissue, inflammation is not induced.
Glaucoma? Finally free from eye drops with SLT laser
30/4/2019
30/4/2019
The prestigious journal The Lancet has published a three-year study on 718 patients from Prof. Gus Gazzard of the Moorfields Eye Hospital which shows how the SLT laser is more effective in treating glaucoma than eye drops, with a possible huge saving on the part of public health care and a concrete improvement in the quality of life of patients.
Soon the laser could take the place of eye drops in Britain to treat glaucoma sufferers, the surprising conclusion of a three-year study. The results, published in the prestigious scientific journal The Lancet, show that the SLT (Selective Laser Trabeculoplasty) laser technique should replace the use of eye drops as the main therapy of glaucoma. The study revealed that SLT is not only more effective and safer but could save state coffers a million and a half pounds a year. "A simple, safe, painless laser treatment that is not only more effective but also more economical," says one of the authors, Prof. Gus Gazzard of London's Moorfields Eye Hospital. "A single laser treatment relieves patients of the obligation to use eye drops every day for the rest of their lives, also avoiding side effects." Side effects associated with glaucoma drug therapies include cataracts, reduced heart rate and fatigue. Glaucoma is one of the main causes of blindness in the world, in Italy it affects one million people but half of them still do not know it and a late diagnosis puts their sight seriously at risk. Most of these patients are prescribed eye drops to lower eye pressure that must be instilled every day for the rest of life, on the contrary SLT can be performed in 15 minutes and only once. The patient sits in front of an instrument similar to a microscope and looks into it while 100 tiny pulses of light hit the eye, restoring the outflow of aqueous humor and lowering the eye pressure. The researchers organized a 3-year study of 718 patients and compared the effectiveness of the two treatments. The results, published on the occasion of World Glaucoma Week, clearly show that patients treated with SLT had lower and more stable eye pressure and fewer complications. The use of SLT treatment could be decisive in countries without a developed health system as it does not require the continuous use of drugs. "This study represents a milestone," says Thomas Brunner, president of the Glaucoma Research Foundation. "In developing countries, SLT could be a fundamental tool to prevent blindness".
Soon the laser could take the place of eye drops in Britain to treat glaucoma sufferers, the surprising conclusion of a three-year study. The results, published in the prestigious scientific journal The Lancet, show that the SLT (Selective Laser Trabeculoplasty) laser technique should replace the use of eye drops as the main therapy of glaucoma. The study revealed that SLT is not only more effective and safer but could save state coffers a million and a half pounds a year. "A simple, safe, painless laser treatment that is not only more effective but also more economical," says one of the authors, Prof. Gus Gazzard of London's Moorfields Eye Hospital. "A single laser treatment relieves patients of the obligation to use eye drops every day for the rest of their lives, also avoiding side effects." Side effects associated with glaucoma drug therapies include cataracts, reduced heart rate and fatigue. Glaucoma is one of the main causes of blindness in the world, in Italy it affects one million people but half of them still do not know it and a late diagnosis puts their sight seriously at risk. Most of these patients are prescribed eye drops to lower eye pressure that must be instilled every day for the rest of life, on the contrary SLT can be performed in 15 minutes and only once. The patient sits in front of an instrument similar to a microscope and looks into it while 100 tiny pulses of light hit the eye, restoring the outflow of aqueous humor and lowering the eye pressure. The researchers organized a 3-year study of 718 patients and compared the effectiveness of the two treatments. The results, published on the occasion of World Glaucoma Week, clearly show that patients treated with SLT had lower and more stable eye pressure and fewer complications. The use of SLT treatment could be decisive in countries without a developed health system as it does not require the continuous use of drugs. "This study represents a milestone," says Thomas Brunner, president of the Glaucoma Research Foundation. "In developing countries, SLT could be a fundamental tool to prevent blindness".
Page intended for healthcare professionals. In compliance with the provisions provided by the Ministry of Health on health advertising relating to medical devices, in vitro diagnostic medical devices and medical-surgical devices, we inform you that the contents of this page are intended exclusively for healthcare professionals. Where present, the description of the products is for information purposes only and is not intended for the promotion of the same.